Mots-clés
 > MYOBASE > BIOLOGIE > biologie par discipline > physiologie > immunité > immunité humorale
immunité humoraleSynonyme(s)humoral immunity |
trié(s) par (Pertinence décroissant(e), Date de parution décroissant(e), Date de parution décroissant(e), Système de projection du document croissant(e)) | Mettre toutes les notices dans le panier | Faire une suggestion | Ajouter un critère de rechercheEtendre la recherche sur niveau(x) vers le bas
Prevalence and long-term monitoring of humoral immunity against adeno-associated virus in Duchenne Muscular Dystrophy patients.
Leborgne C, Latournerie V, Boutin S, et al.
Cellular immunology, 2018, Epub, 10 p.
Necrosis in anti-SRP+and anti-HMGCR+myopathies: Role of autoantibodies and complement.
Allenbach Y, Arouche-Delaperche L, Preusse C, et al.
Neurology, 2018, 90, 6, p. e507-e517
Acetylcholine receptor antibody-mediated animal models of myasthenia gravis and the role of complement.
Kusner LL, Sengupta M, Kaminski HJ
Annals of the New York Academy of Sciences, 2018, 1413, 1, p. 136-142
Myasthenia gravis: the role of complement at the neuromuscular junction
Howard JF Jr
Ann N Y Acad Sci., 2017, Epub, 16 p.
A prospective, placebo controlled study on the humoral immune response to and safety of tetanus revaccination in myasthenia gravis.
Strijbos E, Huijbers MG, van Es IE, et al.
Vaccine, 2017, 35, 46, p. 6290-6296
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
Howard JF, Jr., Utsugisawa K, Benatar M, et al.
The Lancet. Neurology, 2017, Epub, 11 p.
Immunization with Recombinantly Expressed LRP4 Induces Experimental Autoimmune Myasthenia Gravis in C57BL/6 Mice.
Ulusoy C, Cavus F, Yilmaz V, et al.
Immunological investigations, 2017, 10 p.
One year in review 2017: idiopathic inflammatory myopathies.
Barsotti S, Bruni C, Cometi L, et al.
Clinical and experimental rheumatology, 2017, 35, 6, p. 875-884
Advances in serological diagnostics of inflammatory myopathies
Benveniste O, Stenzel W, Allenbach Y
Current opinion in neurology, 2016, 29, 5, p. 662-73
Prevalence and clinical aspects of immigrants with Myasthenia Gravis in northern Europe
Boldingh M, Maniaol A, Brunborg C, et al.
Muscle & Nerve, 2016, Epub, 30 p.
Sporadic inclusion-body myositis: Recent advances and the state of the art in 2016
Gallay L, Petiot P
Revue neurologique, 2016, 172, 10, 6 p.
Recent advances in dermatomyositis-specific autoantibodies
Fujimoto M, Watanabe R, Ishitsuka Y, et al.
Current opinion in rheumatology, 2016, Epub, 9 p.
Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study
Musset L, Allenbach Y, Benveniste O, et al.
Autoimmunity reviews, 2016, Epub, 11 p.
Diagnosis and classification of idiopathic inflammatory myopathies
Lundberg IE, Miller FW, Tjärnlund A, et al.
Journal of internal medicine, 2016, 280, 1, p. 39-51
213th ENMC International Workshop: Outcome measures and clinical trial readiness in idiopathic inflammatory myopathies, Heemskerk, The Netherlands, 18-20 September 2015.
Benveniste O, Rider LG
Neuromuscular disorders : NMD, 2016, Epub, 12 p.
Pompe Disease: Diagnosis and Management. Evidence-Based Guidelines from a Canadian Expert Panel
Tarnopolsky M, Katzberg H, Petrof BJ, et al.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 2016, Epub, 14 p.
Myositis autoantibodies, clinical features, and environmental exposures at illness onset are associated with disease course in juvenile myositis
Habers GE, Huber AM, Mamyrova G, et al.
Arthritis & rheumatology (Hoboken, N.J.), 2016, 68, 3, p. 761-8
The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes
Rider LG, Nistala K
Journal of internal medicine, 2016, Epub, 15 p.
Thymus involvement in myasthenia gravis: Epidemiological and clinical impacts of different self-tolerance breakdown mechanisms
Karni A, Asmail A, Drory VE, et al.
Journal of neuroimmunology, 2016, 298, p. 58-62
Animal models of myasthenia gravis: utility and limitations
Mantegazza R, Cordiglieri C, Consonni A, et al.
International journal of general medicine, 2016, 9, p. 53-64
Future perspectives in target-specific immunotherapies of myasthenia gravis.
Dalakas MC
Therapeutic advances in neurological disorders, 2015, 8, 6, p. 316-327
Interferon-regulated chemokine score associated with improvement in disease activity in refractory myositis patients treated with rituximab
Lopez De Padilla CM, Crowson CS, Hein MS, et al.
Clinical and experimental rheumatology, 2015, 33, 5, p. 655-663
One year in review 2015: idiopathic inflammatory myopathies
Barsotti S, Terenzi R, La Plaglia GM, et al.
Clinical and experimental rheumatology, 2015, 33, 5, p.593-601
The anti-acetylcholine receptor antibody test in suspected ocular myasthenia gravis.
Lee JJ, Koh KM, Kim US
Journal of ophthalmology, 2014, Epub, 4 p.
